ported in carcinomas [13] [14] [15] . The worst prognoses have been noted in patients with hematopoietic disease, neuroblastoma, renal tumor, and mammary cancer in whom survivin expression was high [16] [17] [18] [19] . Previous studies have also reported a relationship between survivin expression and both the prognosis and the cell proliferation kinetics in patients with gastric cancer [20, 21] . In previous clinical studies of cancer, survivin expression has been examined by immunostaining and immunoblotting for the protein; little investigation has been performed at the genetic level [15, [22] [23] [24] . In the present study, we examined the expression of survivin mRNA in gastric cancer by the real-time polymerase chain reaction (PCR) amplification method, and then compared semiquantitative values for survivin mRNA expression with histopathological findings from the cancers, to determine whether the level of survivin mRNA expression could serve as an index of malignancy.
Subjects, materials, and methods

Gastric tissue
Samples were obtained from 107 stomachs surgically resected at the First Department of Surgery, Dokkyo University School of Medicine, between September 1999 and August 2002. Tumors were located in the upper third of the stomach in 23 patients, in the middle third in 47, and in the lower third of the stomach in 37. Total gastrectomy was performed in 21 patients, proximal partial gastrectomy in 2, and distal partial gastrectomy in 84. We obtained 107 cancerous tissue samples, and 107 noncancerous tissue samples that were found more than 3 cm away from cancerous tissue. Informed consent was obtained from all 107 subjects in this study. For each tissue sample, one-half was used for histological diagnosis under standard hematoxylin-eosin staining and the other for survivin mRNA measurements.
Histological diagnosis was performed according to the second English edition of the Japanese classification of gastric carcinoma [25] . Of the 107 cancerous samples, 52 were differentiated (pap, tub1, and tub2) adenocarcinomas and 55 were undifferentiated (sig, por, and muc) adenocarcinomas. When samples were classified by depth of tumor invasion, 28 were T1, 33 were T2, 31 were T3, and 15 were T4. When samples were classified on the basis of lymph node metastasis, 41 were N0, 27 were N1, 19 were N2, and 20 were N3. In addition, hepatic metastasis was recognized in 6 patients and peritoneal metastasis was recognized in 22 patients.
Real-time PCR
Survivin mRNA was detected using a real-time PCR amplification method [26] [27] [28] [29] . Total RNA was extracted from each 5-mg tissue sample by acid guanidine thiocyanate-phenol-chloroform extraction, using RNAzolB (Sawady, Tokyo, Japan) and collected by ethanol precipitation [30] . Complementary DNA was synthesized using a survivin 466-485 primer (5Ј-AGA GGC CTC AAT CCA TGG CA-3Ј) and glyceraldehyde-3-phosphate dehydrogenase (G3PDH), with an exon 8 primer (5Ј-CCT GAT GTC ATC ATA TTT GGC AGG-3Ј) as an internal control. The amplification reaction mixture was prepared using TaqMan Universal Master mix (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). The primer set for amplifying the survivin mRNA was designed according to data from Gene Bank NM001168, using primers for exon 1 (survivin [SVN]-forward [F]): 5Ј-AGA ACT GGC CCT TCT TGG AGG-3Ј and exons 2-3 (SVN-reverse [R]): 5Ј-CTT TTT ATG TTC CTC TAT GGG GTC-3Ј. The probe for these exons (SVN-probe [P]): 5Ј-AGC GGA TGG CCG AGG CTG GCT TC-3Ј) was designed to target an internal region between the SVN-F and SVN-R primers. This primer set did not detect survivin-beta mRNA. The primer set for amplification of the G3PDH mRNA was designed according to data from Gene Bank M33197, using primers for exon 7: 5Ј-TGC ACC ACC AAC TGC TTA GCA CCC-3Ј and exon 8: 5Ј-CTT GAT GTC ATC ATA TTT GGC AGG-3Ј. The probe for G3PDH-P was based on exons 7-8: 5Ј-TGA CCA CAG TCC ATG CCG TCA CTG C-3Ј. Each real-time amplification reaction proceeded for 50 cycles (95°C for 30 s, 60°C for 40 s, and 72°C for 30 s) and was tracked by the ABI Prism 7700 sequence detection system (Perkin-Elmer Applied Biosystems) (Fig. 1) .
The following examination was performed in order to confirm whether the amplified product was indeed survivin. The mRNA amplification products were purified using a commercial kit (Roche Diagnostics, Mannheim, Germany) and directly sequenced using another commercial kit (Thermo Sequence Cy5 Dye Terminator kit; Amersham Pharmacia Biotech, Uppsala, Sweden) and an automated laser fluorescence DNA sequencer (ALF Express; Amersham Pharmacia Biotech). The resulting sequences were compared with target mRNA sequences.
The semiquantitative value for survivin mRNA expression was determined as the index value of the logarithm of the light emission value of the sample RNA relative to that of standard RNA (for example, a value of "5.84" represents 10 5.84 copies per µg total mRNA). Values for results are given as means Ϯ SD unless otherwise stated.
Statistical analysis
Semiquantitative values for survivin mRNA expression in cancerous and noncancerous samples were examined by using the Wilcoxon signed rank test. The semiquantitative values for survivin mRNA expression were compared with histological classification, depth of tumor, and lymph node metastasis, by using the MannWhitney U-test. High and low levels of survivin mRNA expression were compared with histological classification, depth of tumor, and lymph node metastasis, using the 2 test. P values of less than 0.05 were judged to be statistically significant.
Results
Expression of survivin mRNA
Survivin mRNA was detected in 105 of 107 (98.1%) cancerous tissues and in 101 of 107 (94.4%) noncancerous tissues: The mean value of survivin mRNA expression in cancerous tissues was 5.18 Ϯ 1.30, significantly higher (P Ͻ 0.01) than that in noncancerous tissues, at 4.21 Ϯ 1.48 (Figs 2, 3). As survivin mRNA was expressed in most cancerous tissue samples, we divided these samples into these with relatively high and low levels of expression, with the cutoff value being 5.56, the median value of survivin mRNA expression in cancerous tissues.
Relationship between expression of survivin mRNA and histological type
The mean value for survivin mRNA expression in differentiated gastric cancers was 5.17 Ϯ 1.40, not significantly different from that in undifferentiated gastric cancers, at 5.20 Ϯ 1.20 (Table 1) . Of the 52 differentiated cancers, 27 (51.9%) showed high survivin mRNA expression. Of the 55 undifferentiated cancers, 27 (49.1%) showed high survivin mRNA expression. No apparent relationship was found between high survivin mRNA expression and the histological type of gastric cancer; increased survivin expression was thus recog- Fig. 1 . Real-time polynerase chain reaction (PCR) for serial dilutions of a survivin cDNA clone was performed using a one-step method, with a FAM-labeled reporter primer, a TAMRA-labeled quencher primer, and TaqMan Universal Master Mix (PE Applied Biosystems). Reaction mixtures were incubated, and this was followed by 50 cycles of 95°C for 30 s, 60°C for 40 s, and 72°C for 30 s 
Relationship between expression of survivin mRNA and lymph node metastasis
The value for survivin mRNA expression in the 66 patients with lymph node metastasis was 5.48 Ϯ 1.01, significantly higher (P ϭ 0.002) than that in the 41 patients without lymph node metastasis, at 4.70 Ϯ 1.55 (Table 1) . Of the 66 patients with lymph node metastasis, 38 (57.6%) showed high survivin mRNA expression, a significantly higher proportion (P Ͻ 0.05) than the 16 of 41 (39.0%) patients without lymph node metastasis ( Table 1) . No apparent relationship was found between high survivin mRNA expression and degree of lymph node metastasis in the patients with gastric cancer.
Relationship between expression of survivin mRNA and lymph node metastasis according to the depth of tumor invasion
At each invasion depth from T1 to T4, lymph node metastasis was more prevalent in patients who also showed high survivin mRNA expression (Table 4) . However, no significant relationship was found between the level of survivin mRNA expression and lymph node metastasis at any invasion depth, suggesting that high survivin mRNA expression is related only to lymph node metastasis, independent of tumor progression.
Relationship between expression of survivin mRNA and lymphatic invasion
The mean value for survivin mRNA expression in patients with lymphatic invasion was 5.38 Ϯ 1.06, significantly higher (P ϭ 0.016) that that in patients without lymphatic invasion, at 4.52 Ϯ 1.75 (Table 1) . Of the 54 patients displaying high survivin mRNA expression, 45 (83.3%) revealed lymphatic invasion, not significantly different from the 37/53 (69.8%) of patients demonstrating low survivin mRNA expression and lymphatic invasion.
Relationship between expression of survivin mRNA and liver metastasis
The mean value for survivin mRNA expression in the six patients with liver metastasis was 5.77 Ϯ 0.54, not significantly higher than that in patients without liver metastasis, at 5.15 Ϯ 1.32 (Table 1) . High survivin mRNA expression was seen in four of the six patients with liver metastasis (66.7%) and in 50 of the 101 patients without liver metastasis (49.5%); again, not a significant difference.
Relationship between expression of survivin mRNA and venous invasion
The mean value for survivin mRNA expression in the patients with venous invasion was 5.21 Ϯ 1.30, not significantly higher than that in the patients without venous invasion, at 5.13 Ϯ 1.31 (Table 1) . Of the patients displaying high survivin mRNA expression, 66.7% (36/54) also revealed venous invasion, not a significant difference from the 67.9% (36/53) of the patients who showed both low survivin mRNA expression and venous invasion.
Relationship between expression of survivin mRNA and peritoneal metastasis
The mean value for survivin mRNA expression in the 22 patients with peritoneal metastasis was 5.03 Ϯ 1.36, not significantly different from that in the patients without peritoneal metastasis, at 5.22 Ϯ 1.29 (Table 1) . High survivin mRNA expression was seen in 8 of the 22 patients with peritoneal metastasis (36.4%) and in 46 of the 85 patients without peritoneal metastasis (54.1%); again, not a significant difference.
Discussion
The aim of our present study was to investigate quantitative values for the expression of survivin mRNA, indicative of a gene encoding a novel inhibitor of apoptosis, in gastric cancer. Expression of survivin mRNA was detected by the real-time PCR method in 98.1% of cancerous gastric tissues and in 94.4% of noncancerous gastric tissues. The level of survivin mRNA expression was significantly higher in gastric cancer tissue than in noncancerous gastric tissue. However, immunohistochemical analyses of gastric tissue have previously demonstrated that survivin expression could be detected in 34.5% to 82.0% of cancerous gastric cancer tissues, with no survivin expression found in the neighboring normal tissues [20, 21] . Similar studies using immunohistochemical analyses of colorectal, mammary, and skin tissues [14, 19, 31] have also demonstrated survivin expression in cancerous tissues and none in noncancerous tissues. A few studies using immunohistochemical analyses have demonstrated survivin expression in noncancerous colon and lymph node tissues [32, 33] . Survivin expression has also been demonstrated in noncancerous tissue using the reverse transcription-polymerase chain reaction (RT-PCR) method. By this method, survivin mRNA expression was identified in 85.5% of cancerous lung samples and in 12% of paired noncancerous lung samples [24] . Similarly, survivin mRNA expression was detected in 63.5% of cancerous colon samples and in 29.1% of noncancerous colon mucosa samples [23] . In our study, the level of survivin mRNA expression in noncancerous tissue was low in comparison with that in cancerous tissue, but the expression was, nonetheless, observed in 94.4% of the noncancerous tissue samples. This result was very high compared to findings in other reports. Our result was attributed to the increased number of PCR cycles used for the real-time PCR method (50 cycles) in the present study, compared to PCR cycle conditions in other studies using conventional RT-PCR methods (30 to 35 cycles). Using real-time PCR methods, the number of amplification cycles required for the detection of a signal of standard RNA was measured using a known number of existing copies. The result was compared with the results of experimental preparations. Based on this, the quantity of survivin mRNA included in preparations was determined from the number of cycles with confirmed survivin expression. The number of amplifications required for the detection of survivin is more important than the quantity of amplified material created. This study therefore sought to demonstrate the presence of survivin mRNA in noncancerous tissue.
Recently, survivin mRNA has been reported to serve important functions in normal tissues. Survivin is re-quired for the proliferation of cells during conversion in the G2/M-phase and mitotic progression [34, 35] . In addition, the expression of survivin is reported in normal endometrium, where survivin has been demonstrated in the secretory and proliferative phases [36] . Moreover, survivin expression has been identified in normal colonic mucosa in the bases of colonic crypts, which are regarded as proliferation loci [32] . These results show that survivin participates in proliferative functions, supporting the high incidence of survivin mRNA expression in both cancerous and noncancerous gastric tissues shown in the present study.
As survivin mRNA was present in most of our tissue samples, we needed to determine a value above which expression was considered high (i.e., overexpression). We selected the median value of survivin mRNA expression observed in cancerous gastric tissue. Only 15 samples (14.0%) of noncancerous tissue exceeded this cutoff value; this proportion was equal to or less than that determined in other studies using the RT-PCR method. Thus, expression values beneath the cutoff value represent levels at which the expression of survivin is necessary for fundamental cell proliferation in normal tissue.
Of the 107 cancerous gastric tissue samples, 54 showed high survivin mRNA expression and 53 showed low expression. Survivin mRNA expression in these two groups was then compared with the pathological findings. Survivin mRNA expression was independent of both histological type and depth of tumor invasion in patients with gastric cancer. High survivin mRNA expression may therefore occur in the early stages of carcinogenesis of gastric cancer through abnormal control mechanisms, irrespective of the histological type of gastric cancer. This is supported by studies in which survivin expression was observed in precancerous lesions such as Bowen's disease and hypertrophic actinic keratosis preceding cutaneous cancer, and in adenomas, which are the precancerous lesions preceding large-bowel cancer [18, 37] .
In our study, the proportion of patients with high survivin mRNA expression also displaying lymph node metastasis was significantly higher than the proportion of patients with low survivin mRNA expression and lymph node metastasis. This connection between high survivin expression and lymph node metastasis may be related to an earlier finding that survivin expression is connected with microvessel density [38] . Angiogenesis is essential for cancerous tissue to receive adequate nutrition necessary for its continuous growth. Tumors exhibiting high numbers of microvessels have been shown to possess high metastatic potential [39, 40] . Vascular endothelial growth factor (VEGF) has been nominated as one of the triggers of angiogenesis. VEGF expression has also demonstrated a strong association with the presence of lymph node metastasis [41, 42] . Moreover, VEGF stimulation reportedly causes increased expression of survivin [43] . Conversely, survivin may prevent new blood vessels formed by VEGF from disappearing by apoptosis. Thus, VEGF and survivin appear to function cooperatively to increase and maintain newly formed blood vessels. In patients with high survivin expression, newly formed blood vessels are apparently retained, providing greater blood flow to the cancerous tissue and promoting metastasis. In the present study, the value for survivin mRNA expression in the patients with lymphatic invasion was significantly higher that that in the patients without lymphatic invasion. However, no significant differences were found between survivin mRNA expression and vessel invasion.
The relationship between survivin expression and metastasis may also arise from an essential function of survivin: when survivin inhibits apoptosis, the proportion of cancerous cells in a tissue increases with continued growth. Previous studies have indicated that when abnormal cells that would otherwise be removed by apoptosis continue to grow, their potential for invasion and metastasis increases [44, 45] . However, in the present study, no relationship was found between the formation of peritoneal metastasis, a condition related to the invasion ability of the cancer, and survivin expression. Therefore, the increasing likelihood of cancer metastasis from increased angiogenesis seems to describe the relationship between the increased lymph node metastasis and the increased expression of survivin found in the present study.
These results indicate that survivin mRNA expression starts to increase in the early stages of carcinogenesis. Moreover, the level of survivin mRNA expression may indicate the potential for lymph node metastasis.
